5/9/2025

Janusmed sex and gender

Janusmed sex and gender – tocilizumab

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Tocilizumab

Tocilizumab

Class : C

Show all info

Print

Contact us

  1. RoActemra (tocilizumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2024-06-26, cited 2024-10-16]

  2. Neovius M, Simard JF, Askling J, ARTIS study group. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis. 2011;70(4):624-9.

  3. Englund M, Jöud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology (Oxford). 2010;49(8):1563-9.

  4. Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell. 2015;14(3):309-21.

  5. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.

  6. Jättecellsarterit (GCA). 1177 för vårdpersonal [www]. [updated 2023-08-31, cited 2024-10-21].

  7. Berthold E, Månsson B, Kahn R. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden. Arthritis Res Ther. 2019;21(1):218.

  8. Lend K, van Vollenhoven RF, Lampa J, Lund Hetland M, Haavardsholm EA, Nordström D et al. Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial. Lancet Rheumatol. 2022;4(10):e688-e698.

  9. Asai S, Takahashi N, Hayashi M, Hanabayashi M, Kanayama Y, Takemoto T et al. Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab. Joint Bone Spine. 2020;87(6):596-602.

  10. Bordean L, Chis M, Cimpean AM, Barb AC, Cosma AA, Fenesan MP et al. Age, Sex, Metabolic and Pharmacologic Factors May Predict Nonresponse Status to Rheumatoid Arthritis Therapies. In Vivo. 2023;37(5):2387-2401.

  11. Unizony SH, Bao M, Han J, Luder Y, Pavlov A, Stone JH. Treatment failure in giant cell arteritis. Ann Rheum Dis. 2021;80(11):1467-1474.

  12. Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, Donaldson F et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford). 2017;56(4):541-549.

  13. Charan J, Dutta S, Kaur R, Bhardwaj P, Sharma P, Ambwani S et al. Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database. Expert Opin Drug Saf. 2021;20(9):1125-1136.

  14. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. RoActemra (tocilizumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2024-06-26, cited 2024-10-16]
  2. Neovius M, Simard JF, Askling J, ARTIS study group. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis. 2011;70(4):624-9.
  3. Englund M, Jöud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology (Oxford). 2010;49(8):1563-9.
  4. Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell. 2015;14(3):309-21.
  5. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.
  6. Jättecellsarterit (GCA). 1177 för vårdpersonal [www]. [updated 2023-08-31, cited 2024-10-21].
  7. Berthold E, Månsson B, Kahn R. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden. Arthritis Res Ther. 2019;21(1):218.
  8. Lend K, van Vollenhoven RF, Lampa J, Lund Hetland M, Haavardsholm EA, Nordström D et al. Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial. Lancet Rheumatol. 2022;4(10):e688-e698.
  9. Asai S, Takahashi N, Hayashi M, Hanabayashi M, Kanayama Y, Takemoto T et al. Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab. Joint Bone Spine. 2020;87(6):596-602.
  10. Bordean L, Chis M, Cimpean AM, Barb AC, Cosma AA, Fenesan MP et al. Age, Sex, Metabolic and Pharmacologic Factors May Predict Nonresponse Status to Rheumatoid Arthritis Therapies. In Vivo. 2023;37(5):2387-2401.
  11. Unizony SH, Bao M, Han J, Luder Y, Pavlov A, Stone JH. Treatment failure in giant cell arteritis. Ann Rheum Dis. 2021;80(11):1467-1474.
  12. Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, Donaldson F et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford). 2017;56(4):541-549.
  13. Charan J, Dutta S, Kaur R, Bhardwaj P, Sharma P, Ambwani S et al. Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database. Expert Opin Drug Saf. 2021;20(9):1125-1136.
  14. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]